Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| PACIRA (NASDAQ: PCRX) | Delayed: 36.42 +0.08 (0.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.34 | 52 Week High | $80.25 | |||
| Open | $36.33 | 52 Week Low | $30.25 | |||
| Day High | $36.42 | P/E | N/A | |||
| Day Low | $36.33 | EPS | $-2.08 | |||
| Volume | 574,317 | |||||
